Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Plonmarlimab for relapsed/refractory rheumatic disease-associated hemophagocytic lymphohistiocytosis (macrophage activation syndrome)
CTR20253970Phase 3Active
- Sponsor
- Tianjing Biopharma
- Start
- Nov 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of plonmarlimab in haemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), sponsored by Tianjing Biopharma. Started Nov 2025; status: active.
02
Drugs
plonmarlimab
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)macrophage activation syndrome (MAS)
Beyond the preview
Go deeper on CTR20253970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253970.